Receptos Announces Issuance of Composition of Matter Patents Covering Proprietary Lead Product Candidate RPC1063
August 13 2013 - 7:00AM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, announced today that the United States Patent
and Trademark Office (USPTO) has issued U.S. Patent Nos. 8,466,183
and 8,481,573 which cover compounds including the Company's
proprietary selective sphingosine-1-phosphate 1 receptor (S1P1R)
modulator, RPC1063. These composition of matter patents will have
an initial patent term extending to May 2029.
Receptos is pursuing broad patent coverage for its S1P1R
modulator portfolio, including for compositions of matter, multiple
chemical scaffolds as well as certain of their metabolites,
synthetic intermediates, manufacturing methods, and methods of use.
In addition to the issued US patents, multiple additional patent
applications are undergoing prosecution that are anticipated to
provide a strong intellectual property estate around RPC1063.
Faheem Hasnain, President and Chief Executive Officer of the
Company, said, "We are pleased that the USPTO has issued these key
composition of matter patents, which confirm our proprietary
position in the United States for our lead product candidate
RPC1063 until 2029, with the potential for Hatch-Waxman extension.
Robust patent protection for RPC1063 provides the foundation for
investment in multiple indications, including relapsing multiple
sclerosis (RMS) and inflammatory bowel disease (IBD), for which we
have ongoing Phase 2 trials reading out in 2014."
About RPC1063 and S1P1R Modulators
RPC1063 is a novel, oral, once daily, selective and potent S1P1R
modulator in development for autoimmune indications. Previously
reported Phase 1 results demonstrated adequate pharmacokinetic,
pharmacodynamic and safety features, which provide supportive data
for the differentiation strategy for RPC1063 as a potential
best-in-class second generation S1P1R modulator. Receptos is
currently enrolling patients into the randomized Phase 2 portion of
a Phase 2/3 study called RADIANCE examining the efficacy, safety
and tolerability of RPC1063 in RMS and a randomized Phase 2 study
called TOUCHSTONE examining the efficacy, safety and tolerability
of RPC1063 in ulcerative colitis (UC). Top-line results for both
studies are expected in mid-2014.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
Company's lead program, RPC1063, is an S1P1R small molecule
modulator candidate for immune indications, including RMS and IBD.
The Company is also developing RPC4046, an anti-interleukin-13
(IL-13) antibody for an allergic/immune-mediated Orphan Disease,
eosinophilic esophagitis (EoE). Receptos has established expertise
in high resolution protein crystal structure determination, biology
and drug discovery for G-protein-coupled receptors (GPCRs).
Forward-Looking Statements
Statements contained in this release, other than statements of
historical fact, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "expects," "believes," "may," "intends," "potential" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements do not constitute
guarantees of future performance. Investors are cautioned that
forward-looking statements, including without limitation statements
regarding the safety, efficacy and projected development timeline
of drug candidates such as RPC1063 as well as statements regarding
the scope and strength of intellectual property protection,
constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those
anticipated. These forward-looking statements are based upon the
Company's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties, which include without limitation risks associated
with the process of discovering, developing and commercializing
drug candidates that are safe and effective for use as human
therapeutics. These and other risks are described in detail in the
Company's SEC filings, including the Company's Quarterly Reports on
Form 10-Q and the Company's Registration Statement on Form S-1
which was declared effective on May 8, 2013. All forward-looking
statements contained in this release speak only as of the date on
which they were first made by the Company, and the Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after such date.
CONTACT: Media and Investor Contacts:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2023 to Jul 2024